Isolated asymptomatic masseter muscle metastasis as first sign of metastatic disease in a patient with known melanoma

Autor: Caroline Asirvatham Gjorup, Helle Westergren Hendel, Inge Marie Svane, Lisbet Rosenkrantz Hölmich

Publikováno v: JPRAS Open, Vol 10, Iss C, Pp 1-4 (2016)

A 65-year-old woman diagnosed with a nodular melanoma on the right shoulder had a PET/CT scan 13 months later demonstrating a FDG-avid mass in the left masseter muscle, which was asymptomatic and not clinically evident. Pathologic analysis confirmed

Externí odkaz: https://doaj.org/article/7ccc9902907a4fd896e773650aa07bd5

Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma:A National Cohort Study of 1480 Patients

Autor: Neel Maria Helvind, Marie Brinch-Møller Weitemeyer, Annette Hougaard Chakera, Helle Westergren Hendel, Eva Ellebæk, Inge Marie Svane, Mette Wanscher Kjærskov, Sophie Bojesen, Helle Skyum, Søren Kjær Petersen, Lars Bastholt, Christoffer Johansen, Pernille Envold Bidstrup, Lisbet Rosenkrantz Hölmich

Publikováno v: Helvind, N M, Weitemeyer, M B-M, Chakera, A H, Hendel, H W, Ellebæk, E, Svane, I M, Kjærskov, M W, Bojesen, S, Skyum, H, Petersen, S K, Bastholt, L, Johansen, C, Bidstrup, P E & Hölmich, L R 2023, ' Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma : A National Cohort Study of 1480 Patients ', Annals of Surgical Oncology, vol. 30, no. 4, pp. 2377-2388 . https://doi.org/10.1245/s10434-022-13034-6

BACKGROUND: The effect of routine imaging in melanoma surveillance is unknown. In 2016, Denmark was the first country in the world to implement routine imaging with positron emission tomography-computed tomography with fluorodeoxyglucose (FDG PET-CT)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::502dca6532e467018ea220069ced91d8
https://vbn.aau.dk/da/publications/2d930538-311c-42e1-9c99-6e179c1f6a9b

Supplementary Figures 1-6 and Supplementary Table 1 from Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

Autor: Inge Marie Svane, Per thor Straten, Mads Hald Andersen, Özcan Met, Helle Westergren Hendel, Lisbet Rosenkrantz Hölmich, Trine Zeeberg Iversen, Per Kongsted, Troels Holz Borch, Eva Ellebaek, Marco Donia, Rikke Andersen

Supplementary Figure S1. Treatment and monitoring schedule; Supplementary Figure S2. Enrolled patients and number of dropouts; Supplementary Figure S3 The figure shows FDG-PET/CT scans of two responding patients; Supplementary Figure S4. Kaplan-Meier

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ce6efaf19cf232abc56df9e87e6abd4
https://doi.org/10.1158/1078-0432.22457931.v1

Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma

Autor: Eva Ellebaek, Aimilia Schina, Rikke Andersen, Helle Westergren Hendel, Inge Marie Svane, Marco Donia

Publikováno v: Ellebaek, E, Schina, A, Andersen, R, Hendel, H W, Svane, I M & Donia, M 2022, ' Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma ', International Journal of Cancer, vol. 150, no. 11, pp. 1870-1878 . https://doi.org/10.1002/ijc.33926

Routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) may help predict clinical outcomes after response to immunotherapy. With a European Medicines Agency-recommended treatment length until disease progression or unacceptable

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc94bd00b29b5435fc529c81a449773b
https://curis.ku.dk/portal/da/publications/clinical-value-of-routine-18f2fluoro2deoxydglucose-positron-emission-tomography-scans-as-a-decision-tool-for-early-immunotherapy-discontinuation-in-advanced-melanoma(7f25c4f2-e5ba-4d8e-917e-1220a51db328).html

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Autor: Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite, Eva Ellebaek, Marco Donia, Rikke Boedker Holmstroem, Tobias Wirenfeldt Klausen, Cecilie Oelvang Madsen, Shamaila Munir Ahmed, Stine Emilie Weis-Banke, Morten Orebo Holmström, Helle Westergren Hendel, Eva Ehrnrooth, Mai-Britt Zocca, Ayako Wakatsuki Pedersen, Mads Hald Andersen, Inge Marie Svane

Publikováno v: Kjeldsen, J W, Lorentzen, C L, Martinenaite, E, Ellebaek, E, Donia, M, Holmstroem, R B, Klausen, T W, Madsen, C O, Ahmed, S M, Weis-Banke, S E, Holmström, M O, Hendel, H W, Ehrnrooth, E, Zocca, M B, Pedersen, A W, Andersen, M H & Svane, I M 2021, ' A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma ', Nature Medicine, vol. 27, pp. pages2212–2223 . https://doi.org/10.1038/s41591-021-01544-x

Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We tested a first-in-class immune-modulatory vaccine (IO102/IO103) against indoleamine 2,3-d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dd3bba1301f4d5d79e0b554e5fade1b
https://curis.ku.dk/ws/files/314958988/s41591_021_01544_x.pdf